eMagin CorpNYSEMKT
EMA is defunct.
  • Feb. 18, 2014, 9:56 AM
    • Dynavax (DVAX +1.7%) withdraws its application for the European approval of the company's Hepatitis B vaccine Heplisav after the European Medicines Agency (EMA) indicated that the product's safety database is too small to rule out the risk of less common serious side-effects.
    • Dynavax plans to soon start another Heplisav trial in order to provide a large enough database. (PR)
    | Feb. 18, 2014, 9:56 AM | 3 Comments